<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00170690</url>
  </required_header>
  <id_info>
    <org_study_id>3401000</org_study_id>
    <nct_id>NCT00170690</nct_id>
  </id_info>
  <brief_title>Preference Study With Elderly Patients Recurrent Ovarian Cancer</brief_title>
  <official_title>Präferenz-Studie Bei älteren Patientinnen Mit Ovarialkarzinomrezidiv: Treosulfan Oral vs. intravenös</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>North Eastern Germany Society of Gynaecologic Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>North Eastern Germany Society of Gynaecologic Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of the patient compliance treosulfan oral vs. intravenous (defined as end of
      therapy for the patient)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 60% of all cancer diseases appear to people aged 65 years and older. Ovarian
      cancer is the most frequent cause of death among gynaecological malignant tumours. Since the
      highest carcinoma incidence is between the 60th and 70th year more women will come down with
      ovarian cancer because of increased life expectancy. At least 65% of patients with FIGO stage
      III/IV will exhibit a relapse or progress after first-line therapy. In most studies the age
      of the patients is limited to 65 years. It could be shown that especially elder patients
      often receive an inadequate operative and cytostatic therapy resulting in a worse prognosis.

      Patients aged 70 years or elder who will be treated with treosulfan, given oral or
      intravenous, shall be compared regarding the patient compliance, toxicity especially
      hematological and gastrointestinal toxicity grade 3-4 (CTC NCI), overall survival,
      progression free survival, quality of life.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of patient´s compliance in both arms defined as therapy break-offs</measure>
    <time_frame>during study treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity, overall survival, progression-free survival</measure>
    <time_frame>during study treatment and follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">123</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treosulfan 7000 mg/m² i.v. on day 1, 29, 57 etc</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treosulfan 600 mg/m² p.o. on day 1-28, 57-84, etc</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treosulfan</intervention_name>
    <description>Treosulfan 600 mg/m² p.o. on daý 1-28, 57-84, etc</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treosulfan</intervention_name>
    <description>Treosulfan 7000 mg/m² i.v. on day 1, 29, 57 etc</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient with relapsed ovarian cancer

          -  study therapy of third regime

          -  measurable or evaluable tumor lesions or progression defined as CA-125 more than &gt;=
             100 U/ ml.

          -  Age &gt;= 70 years

          -  ECOG 0-2

          -  written informed consent

        Exclusion Criteria:

          -  Pretreatment with treosulfan

          -  patient without measurable or evaluable tumor lesions or CA-125 more than &gt;= 100 U/
             ml.

          -  no adequate bone marrow function (leukocyte &lt;= 2,9 x 109/l, platelets &lt;= 100 x 109/ l

          -  creatinin and bilirubin within &gt;= 1,25 x fold of the reference laboratory´s normal
             range

          -  simultaneous radiotherapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jalid Sehouli</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charité Campus Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13533</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>May 31, 2013</last_update_submitted>
  <last_update_submitted_qc>May 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2013</last_update_posted>
  <responsible_party>
    <name_title>W. Lichtenegger, Prof. Dr.</name_title>
    <organization>Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Treosulfan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

